Study Links Z-Pak To Cardiovascular Death Risk

October 11, 2013

Important Information

Attorneys working with ClassAction.org are no longer investigating this matter. The information here is for reference only. A list of open investigations and lawsuits can be viewed here.

Comments |

At A Glance

This Alert Affects
Patients who took antibiotic Z-Pak, also known as Zithromax and azithromycin.
Damages
Compared to patients taking no antibacterial drug or an alternative antibiotic, patients taking Z-Pak have a slightly increased risk of suffering a cardiovascular death, according to a study in the New England Journal of Medicine.
Company(ies)
Pfizer
Additional Details
Z-Pak belongs to a class of drugs known as macrolides. This class of antibacterial drugs has been linked to cardiovascular effects, specifically prolongation of the QT interval which can lead to an abnormal and sometimes-fatal heart rhythm.
Date
On May 17, 2012, the FDA notified healthcare professionals of a study published in the New England Journal of Medicine which reported a small increase in cardiovascular deaths in patients treated with a 5-day azithromycin compared to those taking another antibiotic or no antibacterial drug at all.